TABLE 1.
Characteristics of the study cohortb
| No/low viral load (<1,000 copies/ml) (n = 69) | Viremia (>1,000 copies/ml) (n = 68) | P valuea | |
|---|---|---|---|
| Gender (% female) | n = 29 (42%) | n = 36 (53%) | ns |
| Median age, yr (range) | 57.9 (19–66) | 53.5 (18–71) | ns |
| D/R serostatus | ns | ||
| D+/R− | n = 17 (24.6%) | n = 19 (28.0%) | |
| D−/R+ | n = 24 (34.8%) | n = 13 (19.1%) | |
| D+/R+ | n = 28 (40.6%) | n = 36 (52.9%) | |
| Viral load (copies/ml plasma) (min–max) | |||
| n (%) | n = 31 (44.9%) | ||
| Median days post-LTX (min–max) | 150 (65–319) | ||
| Median viral load (copies/ml plasma) (min–max) | 141 (126–454) | ||
| 1st highly viremic episode | |||
| n (%) | n = 68 (100%) | ||
| Median days post-LTX (min–max) | 141 (26–454) | ||
| Median viral load (copies/ml plasma) (min–max) | 4.3 × 103 (1,400–1.4 × 106) | ||
| 2nd highly viremic episode | |||
| n (%) | n = 25 (36.8%) | ||
| Median days post-LTX (min–max) | 194 (113–587) | ||
| Median viral load (copies/ml plasma) (min–max) | 2.7 × 103 (1,060–9.2 × 104) | ||
| 3rd highly viremic episode | |||
| n (%) | n = 2 (2.9%) | ||
| Mean days post-LTX (min–max) | 370 (113–587) | ||
| Mean viral load (copies/ml plasma) (min–max) | 1.5 × 103 (1,240–3,130 × 103) | ||
| 4th highly viremic episode | |||
| n (%) | n = 1 (1.5%) | ||
| Days post-LTX | 492 | ||
| Viral load (copies/ml plasma) | 1.1 × 103 | ||
a
Differences between groups were assessed with the Mann-Whitney or χ2 test.
b
Abbreviations: D+, HCMV-seropositive donor; D−, HCMV-seronegative donor; ns, not significant; R+, HCMV-seropositive recipient; R−, HCMV-seronegative recipient; LTX, lung transplantation.